Screener
Stryker SYK MedSurg and Neurotechnology — Foreign exchange and other
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stryker in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: Stryker’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 11:10 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000310764-26-000031
FAQ
- What is Stryker's medsurg and neurotechnology — foreign exchange and other?
- Stryker (SYK) reported medsurg and neurotechnology — foreign exchange and other of -$19M in Q1 2026.
- How has Stryker's medsurg and neurotechnology — foreign exchange and other changed year-over-year?
- Stryker's medsurg and neurotechnology — foreign exchange and other decreased by 204.1% year-over-year, from $18.25M to -$19M.
- What is the long-term trend for Stryker's medsurg and neurotechnology — foreign exchange and other?
- Over 4 years (2021 to 2025), Stryker's medsurg and neurotechnology — foreign exchange and other has grown at a 53.9% compound annual growth rate (CAGR), from -$13M to $73M.
- What does medsurg and neurotechnology — foreign exchange and other mean?
- This metric quantifies the impact of currency fluctuations and miscellaneous non-operational factors on the MedSurg and Neurotechnology segment's financial results. It isolates the variance in revenue or earnings caused by changes in exchange rates between the reporting currency and the currencies of international markets where the segment operates. Monitoring this helps distinguish between organic business growth and gains or losses driven by global macroeconomic volatility.
Ask your AI about Stryker's medsurg and neurotechnology — foreign exchange and other.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude